Seres Therapeutics annual revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Seres Therapeutics Revenue Growth & History (MCRB)
Seres Therapeutics reported $789,000 in revenue for fiscal 2025.
View full Seres Therapeutics company overviewSeres Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $789,000 | $789,000 | — |
| 2024 | 2024-12-31 | $0 | $0 | — |
| 2023 | 2023-12-31 | $0 | −$7.1M | −100.00% |
| 2022 | 2022-12-31 | $7.1M | −$136.7M | −95.05% |
| 2021 | 2021-12-31 | $143.9M | $132.0M | +1109.19% |
| 2020 | 2020-12-31 | $11.9M | −$15.3M | −56.24% |
| 2019 | 2019-12-31 | $27.2M | $271,000 | +1.01% |
| 2018 | 2018-12-31 | $26.9M | −$5.2M | −16.15% |
| 2017 | 2017-12-31 | $32.1M | $10.3M | +47.48% |
| 2016 | 2016-12-31 | $21.8M | $21.8M | — |
| 2015 | 2015-12-31 | $0 | — | — |
Seres Therapeutics quarterly revenue
Q2.14
Q3.14
Q2.15
Q3.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $736,000 | $736,000 | — |
| Q1 2026 | 2026-03-31 | $358,000 | $358,000 | — |
| Q4 2025 | 2025-12-31 | $438,000 | $438,000 | — |
| Q3 2025 | 2025-09-30 | $351,000 | $351,000 | — |
| Q2 2025 | 2025-06-30 | $0 | $0 | — |
| Q1 2025 | 2025-03-31 | $0 | $0 | — |
| Q4 2024 | 2024-12-31 | $0 | $126.3M | +100.00% |
| Q3 2024 | 2024-09-30 | $0 | −$310,000 | −100.00% |
| Q2 2024 | 2024-06-30 | $0 | −$126.5M | −100.00% |
| Q1 2024 | 2024-03-31 | $0 | $522,000 | +100.00% |
| Q4 2023 | 2023-12-31 | −$126.3M | −$127.2M | −13049.85% |
| Q3 2023 | 2023-09-30 | $310,000 | −$3.1M | −91.00% |
| Q2 2023 | 2023-06-30 | $126.5M | $125.3M | +10300.74% |
| Q1 2023 | 2023-03-31 | −$522,000 | −$2.0M | −134.96% |
| Q4 2022 | 2022-12-31 | $975,000 | −$6.2M | −86.50% |
| Q3 2022 | 2022-09-30 | $3.4M | −$123.3M | −97.28% |
| Q2 2022 | 2022-06-30 | $1.2M | −$4.0M | −76.90% |
| Q1 2022 | 2022-03-31 | $1.5M | −$3.2M | −67.88% |
| Q4 2021 | 2021-12-31 | $7.2M | $6.1M | +517.71% |
| Q3 2021 | 2021-09-30 | $126.7M | $126.6M | +158306.25% |
| Q2 2021 | 2021-06-30 | $5.3M | $77,000 | +1.48% |
| Q1 2021 | 2021-03-31 | $4.6M | −$814,000 | −14.90% |
| Q4 2020 | 2020-12-31 | $1.2M | −$4.1M | −77.86% |
| Q3 2020 | 2020-09-30 | $80,000 | −$4.8M | −98.35% |
| Q2 2020 | 2020-06-30 | $5.2M | −$5.3M | −50.39% |
| Q1 2020 | 2020-03-31 | $5.5M | −$1.2M | −17.43% |
| Q4 2019 | 2019-12-31 | $5.3M | −$4.9M | −48.22% |
| Q3 2019 | 2019-09-30 | $4.8M | −$3.8M | −44.27% |
| Q2 2019 | 2019-06-30 | $10.5M | $6.2M | +144.77% |
| Q1 2019 | 2019-03-31 | $6.6M | $2.8M | +75.65% |
| Q4 2018 | 2018-12-31 | $10.2M | $7.1M | +233.64% |
| Q3 2018 | 2018-09-30 | $8.7M | −$14.3M | −62.27% |
| Q2 2018 | 2018-06-30 | $4.3M | $1.3M | +41.71% |
| Q1 2018 | 2018-03-31 | $3.8M | $751,000 | +24.91% |
| Q4 2017 | 2017-12-31 | $3.1M | $19,000 | +0.63% |
| Q3 2017 | 2017-09-30 | $23.0M | $10.0M | +76.83% |
| Q2 2017 | 2017-06-30 | $3.0M | $10,000 | +0.33% |
| Q1 2017 | 2017-03-31 | $3.0M | $305,000 | +11.25% |
| Q4 2016 | 2016-12-31 | $3.0M | — | — |
| Q3 2016 | 2016-09-30 | $13.0M | $13.0M | — |
| Q2 2016 | 2016-06-30 | $3.0M | $3.0M | — |
| Q1 2016 | 2016-03-31 | $2.7M | — | — |
| Q3 2015 | 2015-09-30 | $0 | $0 | — |
| Q2 2015 | 2015-06-30 | $0 | $0 | — |
| Q3 2014 | 2014-09-30 | $0 | — | — |
| Q2 2014 | 2014-06-30 | $0 | — | — |
Seres Therapeutics revenue growth trends
Over the last five reported fiscal years, revenue declined from $11.9M to $789,000, a compound annual decline of 41.88%. Seres Therapeutics's latest reported quarter, Q2 2026, generated $736,000 in revenue.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Seres Therapeutics source filings ↗